Rune Labs has released an AI companion designed specifically for people with Parkinson’s disease. The tool, called StrivePD Guardian, runs on Anthropic’s Claude AI system and draws from what the company calls the world’s largest Parkinson’s dataset.

The AI analyzes real-time patient data from wearables to offer guidance on symptoms, medications, and daily care decisions. Unlike general AI chatbots, this system is built specifically for Parkinson’s patients and their unique needs.

How does it work?

StrivePD Guardian uses multiple specialized AI agents that handle different aspects of Parkinson’s care. When a patient asks a question, the system automatically routes it to the most appropriate specialist agent without requiring menu navigation.

The system learns from several data sources:

• Wearable device readings that track movement and symptoms
• Medication logs and timing records
• Patient journal entries and chat history
• User-defined health goals and preferences

“It’s like having a conversation with my own StrivePD data,” said Kevin K., a user testing the system. “I can ask questions, get quick answers, all grounded in what I’ve logged.”

The AI builds a continuously updated patient profile that becomes more personalized over time. It can interpret complex Parkinson’s symptoms like “off times” and dyskinesia by matching patient reports with objective movement data from wearables.

Why does it matter?

Parkinson’s symptoms change throughout the day, making it difficult for patients to track patterns and communicate effectively with doctors. CEO Amy Franzen explains that “People with Parkinson’s live with symptoms that change hour-to-hour.”

The AI companion addresses several key challenges:

• Provides immediate answers when symptoms or concerns arise
• Helps patients identify patterns in their condition over time
• Prepares patients for more productive doctor visits
• Offers 24/7 support without burdening healthcare teams

The system includes safety measures built in. It uses careful language and directs patients to contact doctors or seek emergency care when symptoms require immediate medical attention.

The context

Rune Labs built this AI using millions of hours of real patient data collected through wearable devices and FDA-cleared symptom tracking algorithms. This gives it a level of medical specificity that general-purpose AI tools lack.

“Because StrivePD Guardian is trained on our continuous wearable datasets, it can interpret ‘off times’ and dyskinesia with a level of precision that general-purpose AI models simply cannot achieve,” said William Newby, the company’s Vice President of Product and Strategy.

The tool is now available for download from the App Store. Existing StrivePD users can upgrade within their current app, though AI chat access varies by subscription plan. Healthcare providers can also offer the tool through partner programs to support patient monitoring and care coordination.

Rune Labs specializes in precision neurology and works with both patients and pharmaceutical companies developing new Parkinson’s treatments. The company uses its large dataset and network of patients to help speed up clinical trials and drug development programs.

The post Rune Labs launches AI companion for Parkinson’s patients trained on massive medical dataset appeared first on mHealth Spot.

Google is making major changes to how its Gemini AI handles mental health crises. The company announced new safety features that will connect users more directly to professional help when conversations suggest someone might be in danger.

The tech giant is also putting $30 million behind the effort over three years to help crisis hotlines around the world expand their services. Mental health affects over one billion people globally, and Google says it wants its AI tools to play a positive role rather than create new problems.

How does it work?

When Gemini spots a conversation that might indicate suicide risk or self-harm, it will now show a simplified ‘one-touch’ interface. This connects users directly to crisis hotline resources where they can:

• Start a chat session
• Make a phone call
• Send a text message
• Visit the crisis hotline website

The system keeps these help options visible for the rest of the conversation once activated. Google developed this with clinical experts and says it’s designed to encourage people to actually seek help.

For less urgent mental health discussions, Gemini will show an updated ‘Help is available’ module that points users toward appropriate resources and information.

Why does it matter?

More people are having complex, personal conversations with AI chatbots like Gemini. This includes discussions about mental health crises, which puts pressure on companies to handle these situations responsibly.

Google admits that AI tools can create new challenges for mental health support. But as these tools become part of daily life for millions of users, the company believes they need to connect people to real human help when it matters most.

The $30 million in funding will help crisis hotlines scale up their capacity to handle more people reaching out for immediate support. Google is also expanding its partnership with ReflexAI, including $4 million in direct funding to help organizations train their mental health support staff using AI-powered simulations.

The context

Google has specific protections for younger users of Gemini, including responses designed to avoid harmful topics. The company’s clinical, engineering, and safety teams have been training the AI model to recognize when someone might be in an acute mental health situation.

The company is clear that Gemini isn’t a replacement for professional therapy or crisis support. Instead, it’s trying to make the AI better at recognizing when users need real help and connecting them to it quickly.

These changes are part of Google’s longer-term effort to use its technology responsibly in mental health situations. The company says it wants to make support more accessible and effective, while creating a safer digital environment for people to explore and learn.

The post Google updates Gemini AI with mental health crisis support and commits $30 million to helplines appeared first on mHealth Spot.

Samsung is pushing Galaxy XR beyond gaming and entertainment with a major software update that brings enterprise features to the mixed reality headset. The company announced today that Galaxy XR now supports Android Enterprise, the same management framework that IT departments use to control millions of Android phones and tablets.

The update also promises five years of regular software updates and security patches. That’s a significant commitment for XR hardware, which typically sees shorter support cycles than smartphones.

How does it work?

Android Enterprise gives IT administrators the tools they need to manage Galaxy XR devices at scale. The system works the same way it does on phones – administrators can:

• Control which apps employees can install
• Push security policies across all devices
• Remotely wipe devices if they’re lost or stolen
• Monitor usage and performance

Samsung Knox adds another layer of security on top of Android Enterprise. The hardware-based security platform creates a secure container for sensitive business data, keeping it separate from personal apps and content.

Why does it matter?

Most XR headsets today are designed for consumers or early adopters willing to deal with rough edges. Enterprise customers need something different – reliable hardware, predictable software updates, and management tools that work with their existing IT infrastructure.

Samsung is targeting specific business use cases:

• Employee training programs in manufacturing and healthcare
• Retail product demonstrations and virtual showrooms
• Remote collaboration for distributed teams
• Design and engineering visualization

The five-year support commitment matters too. Businesses can’t justify buying expensive hardware that might become obsolete in two years. Samsung is essentially promising that Galaxy XR will stay secure and functional until 2030.

The context

Samsung launched Galaxy XR in October 2025 as its first major push into mixed reality. The device runs Android XR, Google’s XR-focused version of Android that competes with Meta’s Horizon OS and Apple’s visionOS.

The enterprise focus makes sense given the current state of the XR market. Consumer adoption remains slow, but businesses are starting to find real value in XR for training and collaboration. Meta has seen success with Quest for Business, while Microsoft’s HoloLens built its reputation primarily in enterprise.

James Choi, who heads XR development at Samsung, said the company sees enterprise as central to its XR strategy. “Our vision for XR extends beyond hardware – it’s about building a secure, scalable ecosystem informed by our users,” he said in a statement.

The software update rolls out starting today for existing Galaxy XR users. Samsung hasn’t said whether the enterprise features will cost extra or come standard with all devices.

The post Samsung Galaxy XR gets Android Enterprise support for business users appeared first on mHealth Spot.

Doctors already use AI scribes to record patient consultations and create notes automatically. But new research shows these systems work much better when they can see what’s happening, not just hear it.

A study from Flinders University tested AI scribes fitted with Ray-Ban Meta smart glasses. The vision-enabled system achieved 98% accuracy in documenting patient consultations, compared to 81% for audio-only versions. The research was published in npj Digital Medicine.

The difference was particularly stark when recording medication details. The AI with video captured crucial information like drug strength and form 97% of the time. Audio-only systems managed just 28%.

How does it work?

The researchers used Google’s Gemini AI model combined with Ray-Ban Meta smart glasses to create their vision-enabled scribe system. Here’s the process:

• Clinical pharmacists wore the smart glasses during mock patient consultations
• The glasses recorded both video and audio of the interactions
• The AI analyzed visual elements like medicine containers, prescriptions, and patient body language
• It combined this visual data with spoken information to create comprehensive notes

The study involved 10 pharmacists conducting 110 simulated medication-history interviews with more than 100 different types of medicines, including tablets, capsules, injections, and creams.

Why does it matter?

Medical documentation takes up huge amounts of clinicians’ time. AI scribes already help reduce this burden, but accuracy problems mean doctors still need to spend time checking and correcting the notes.

“A lot of clinically important information is visual,” says research author Bradley Menz. “Important visual cues during consultations include patients’ medicine containers, prescriptions and devices, as well as their body language.”

Better accuracy means less time spent editing AI-generated notes. This could free up even more time for actual patient care. The visual component also captures critical safety information that audio-only systems miss entirely.

The researchers stress this is an “augmented tool, not a replacement for clinical judgment.” Doctors still need to review and approve all AI-generated documentation.

The context

AI scribes have gained popularity in healthcare because they reduce administrative work that keeps doctors away from patients. But current systems have significant limitations when important information is communicated visually.

This study suggests the next generation of AI scribes will need visual capabilities to be truly effective. Associate Professor Ashley Hopkins, the senior author, believes this could “open the door to wider clinical uses” for AI scribes.

However, the researchers acknowledge several challenges before vision-enabled AI scribes can be widely adopted:

• Privacy concerns about video recording in medical settings
• Patient consent for visual documentation
• Data security for video files
• Integration with existing hospital workflows
• Need for careful governance and oversight

The study used simulated consultations, so real-world testing will be needed before these systems can be deployed in actual clinical settings. But the accuracy improvements suggest vision-enabled AI scribes could become the new standard for medical documentation.

The post AI medical scribes get smart glasses upgrade for better patient notes appeared first on mHealth Spot.

Anthropic has acquired stealth biotech AI startup Coefficient Bio in a $400 million stock deal. The Information and Eric Newcomer first reported the acquisition, with sources close to the deal confirming to TechCrunch that it closed, though they wouldn’t comment on the price.

The purchase comes as the Claude AI maker pushes deeper into healthcare and life sciences. In October, Anthropic launched Claude for Life Sciences, a tool designed to help researchers make scientific discoveries.

What’s the news?

Coefficient Bio’s founders, Samuel Stanton and Nathan C. Frey, started the company just eight months ago. Both previously worked in computational drug discovery at Genentech’s Prescient Design unit.

The startup used AI to make drug discovery and biological research more efficient. The team of around 10 people will join Anthropic’s health and life sciences group.

Why does it matter?

This acquisition shows Anthropic is serious about competing in the healthcare AI space. The company gains:

• Experienced drug discovery talent from a major pharmaceutical company
• AI expertise specifically focused on biological research
• A ready-made team to expand its life sciences offerings

The $400 million price tag for an eight-month-old startup with 10 employees highlights how much value AI companies place on specialized talent and domain expertise.

The context

AI companies are racing to find applications beyond chatbots and coding assistants. Healthcare represents a massive opportunity, with potential applications in drug discovery, medical imaging, and clinical research.

Anthropic faces competition from OpenAI, Google, and other AI giants who are also targeting healthcare markets. The Coefficient Bio acquisition gives Anthropic specialized knowledge that could help it stand out in this crowded field.

The deal also reflects the broader trend of AI companies acquiring talent-rich startups rather than building expertise from scratch. With competition for AI researchers intense, buying entire teams has become an expensive but effective strategy.

The post Anthropic buys AI biotech startup Coefficient Bio for $400 million appeared first on mHealth Spot.

Insilico Medicine has signed a major drug discovery partnership with pharmaceutical giant Eli Lilly. The deal could be worth up to $2.75 billion and focuses on using artificial intelligence to speed up the development of new medicines.

The Hong Kong-listed biotech company will get $115 million upfront, with additional payments tied to hitting development and sales targets. Lilly gets exclusive worldwide rights to develop and sell the resulting drugs.

How will it work?

The partnership combines Insilico’s AI platforms with Lilly’s drug development experience. Here’s what each company brings:

• Insilico provides its Pharma.AI technology that can identify drug targets and design molecules
• Lilly contributes its clinical development capabilities and disease expertise
• The companies will work together on multiple research programs targeting diseases chosen by Lilly
• Insilico’s AI can supposedly identify targets that affect multiple diseases simultaneously

Lilly gets exclusive rights to develop, manufacture, and sell any drugs that come out of this collaboration. The focus is on oral medicines currently in preclinical development.

Why does it matter?

This deal shows how big pharmaceutical companies are betting on AI to solve drug discovery problems. Traditional drug development is slow and expensive – it typically takes over a decade and costs billions to bring a new medicine to market.

AI promises to speed this up by:

• Identifying new drug targets faster
• Designing molecules more efficiently
• Predicting which compounds are most likely to work
• Reducing the number of failed experiments

For Insilico, the partnership provides validation of its technology and significant funding. For Lilly, it’s a way to expand its pipeline across multiple disease areas without building AI capabilities in-house.

The context

Insilico Medicine is part of a wave of AI-focused biotech companies that have emerged in recent years. The company went public in Hong Kong in 2023 and has been working to prove its technology can actually deliver new drugs.

“From its inception, Insilico Medicine has been developing deep learning for end-to-end drug discovery,” said Alex Zhavoronkov, the company’s founder and CEO. The company claims its AI can create “world models of human and animal life” to identify drug targets.

Lilly, meanwhile, has been actively seeking partnerships to boost its drug pipeline. “Insilico’s AI-enabled discovery capabilities represent a powerful complement to Lilly’s deep expertise in clinical development,” said Andrew Adams, Group Vice President of Molecule Discovery at Lilly.

The pharmaceutical industry has seen several similar AI partnerships recently, as established drug companies look to new technologies to improve their hit rates in drug discovery.

The post Insilico Medicine partners with Eli Lilly in $2.75 billion AI drug discovery deal appeared first on mHealth Spot.

Samsung dropped a surprise today. The company announced Hearapy, a new mobile app that helps people deal with motion sickness during travel and car rides.

The app has one job. It plays a precise 100 Hz sine wave that stimulates your inner ear’s balance system. Listen for a minute, and you might avoid motion sickness for up to two hours.

How does it work?

Hearapy isn’t magic. Samsung based the app on research from Nagoya University in Japan. The researchers studied which sound frequencies best stimulate the vestibular system – the part of your inner ear that controls balance.

Their study found that listening to a 100 Hz sine wave at 75-85 decibels for several minutes can temporarily improve your balance. Samsung claims just 60 seconds of listening provides up to two hours of relief from motion sickness.

The app works with most headphones, not just Samsung’s own. We tested it and found it functions with various headphone brands, though results may vary between users.

Why does it matter?

Motion sickness affects millions of people during car rides, flights, and boat trips. Current solutions include:

• Prescription medications that can cause drowsiness
• Over-the-counter pills that don’t work for everyone
• Wristbands and other devices with mixed results

A free app that works in 60 seconds could be a simple alternative. You don’t need to plan ahead or deal with side effects.

The context

Samsung announced Hearapy alongside its new Galaxy Buds 4 Pro wireless earbuds. The company specifically mentions these earbuds “deliver clean and powerful 100 Hz sound.” This suggests the app might work best with Samsung’s latest earbuds, though the company hasn’t confirmed this.

The timing isn’t accidental. Samsung wants to show that its new earbuds can do more than just play music or take calls.

You can download Hearapy now from Google Play. The app is free, so there’s little risk in trying it before your next trip.

The post Samsung’s new Hearapy app fights motion sickness with sound waves appeared first on mHealth Spot.

Americans are asking AI systems more health questions than ever before. But these conversations happen outside the healthcare system, without access to your actual medical records. That means the advice you get might not fit your specific health situation.

Hartford HealthCare and K Health just launched PatientGPT, an AI system that can securely read your medical records and connect you directly to doctors when needed. The tool works inside Hartford HealthCare’s patient portal and is starting as a beta test with a limited number of patients.

PatientGPT runs 24 hours a day and gives personalized health education based on your medical history. It can also set up virtual visits or in-person appointments with your care team.

How does it work?

PatientGPT uses specialized AI agents that work within the hospital’s secure computer systems. Patients access it through a link in their Hartford HealthCare patient portal. The system can:

• Answer health questions using your medical records
• Connect you to Hartford HealthCare doctors through virtual visits
• Schedule appointments with primary care doctors or specialists
• Ask follow-up questions to better understand your concerns
• Send chat summaries to your doctors before appointments

The system won’t diagnose conditions or prescribe treatments. It’s designed to hand off complex cases to human doctors when needed. Only patients 18 and older in Connecticut can use it right now.

Why does it matter?

Most health AI tools work like dead ends – they give you information but can’t connect you to actual medical care. PatientGPT bridges that gap by linking education with real healthcare access.

For patients, this means getting health guidance that actually relates to their medical history. For doctors, it means patients come to appointments better prepared and routine questions get answered ahead of time.

“So much of healthcare has traditionally been organized around the provider, but it’s clear we have to meet people where they are,” said Jeff Flaks, Hartford HealthCare’s CEO. “PatientGPT supports your health and provides access to a 24/7 care team, while protecting the human relationships at the heart of care.”

The system helps doctors focus more time on diagnosis and decision-making instead of answering basic informational questions.

The context

K Health spent nearly a decade building AI systems that understand medical language – symptoms, medications, and treatment options. The company already partners with major health systems like Cedars-Sinai and Hackensack Meridian Health.

Hartford HealthCare is rolling out PatientGPT carefully, with oversight from licensed doctors and quality monitoring. The system includes built-in safety checks that review responses against clinical guidelines.

“Patients are already using AI to navigate their lives,” said Allon Bloch, K Health’s CEO. “The question isn’t whether AI will shape healthcare, it’s about how we do it in a safe, transparent way, inside a health system that connects to your medical records and your care team.”

Hartford HealthCare serves over 28,000 people daily across Connecticut through more than 500 locations. The health system has received top safety ratings and was the only system in the country to win the American Hospital Association’s Quest for Quality Prize.

The post New AI system reads your medical records and answers health questions 24/7 appeared first on mHealth Spot.

Samsung has launched blood pressure monitoring for Galaxy Watch users in the United States. The feature works with Galaxy Watch4 and newer models through the Samsung Health Monitor app.

The timing is significant. Nearly half of all US adults – about 119.9 million people – have high blood pressure according to the CDC. Poor management of blood pressure increases the risk of heart disease and stroke, which are leading causes of death in America.

How does it work?

The blood pressure feature uses Samsung’s calibration technology to estimate your readings. Here’s what you need to know:

• Users must calibrate their watch with an upper arm cuff every 28 days
• The watch measures both systolic and diastolic blood pressure
• It uses the same internal sensors that track heart rate
• The upper arm cuff is sold separately

Samsung plans to add passive monitoring later this year. This will show blood pressure trends over time without requiring active measurements.

Why does it matter?

The feature gives users more insight into their health directly from their wrist. This can help people make better health decisions and maintain a healthier lifestyle. However, Samsung notes the feature is not intended to prevent or diagnose high blood pressure.

Blood pressure monitoring joins Samsung’s growing health toolkit, which includes:

• Sleep apnea detection (the first FDA-authorized feature of its kind)
• ECG readings and irregular heart rhythm notifications
• 24/7 heart rate monitoring
• Sleep tracking and ectopic beat detection

The context

This launch puts Samsung in direct competition with other health-focused wearables. The company has been building its health platform around the Samsung Health app, which now offers what Samsung calls an “end-to-end health and wellness platform.”

The feature is available on the Galaxy Watch4 series and newer models, including the latest Galaxy Watch8 and Galaxy Watch8 Classic. Both newer models include advanced sensors and AI-powered health experiences.

The blood pressure feature is currently limited to select Galaxy users in the US. Samsung has not announced plans for broader availability.

The post Samsung Galaxy Watch now tracks blood pressure in the US appeared first on mHealth Spot.

WHOOP has closed a massive $575 million Series G funding round, valuing the wearable health company at $10.1 billion. The Boston-based startup attracted an impressive list of backers, from healthcare giant Abbott to sports superstars Cristiano Ronaldo and LeBron James.

The round was led by Collaborative Fund, with participation from sovereign wealth funds Qatar Investment Authority and Mubadala Investment Company. Healthcare heavyweight Mayo Clinic also joined the round, alongside a roster of elite athletes including Rory McIlroy, Reggie Miller, and Virgil van Dijk.

The money will be used for…

WHOOP plans to accelerate its international expansion across Europe, the Gulf states, Latin America, and Asia. The company currently ships to 56 countries but sees major growth opportunities in new markets.

The funding will also help WHOOP build what it calls “the world’s leading personal health platform.” This includes:

• Expanding its AI-powered health insights using data from over 24 billion hours of physiological monitoring
• Developing new features for disease prevention and early warning systems
• Scaling its platform to handle millions more users globally

Why does it matter?

WHOOP is betting big on a shift from reactive to preventive healthcare. The company argues that rising chronic disease rates and strained healthcare systems create an opportunity for continuous health monitoring that can predict problems before they happen.

The engagement numbers suggest users are buying into this vision. WHOOP members check the app over eight times per day – nearly three times more than users of other screenless wearables. The device tracks sleep, recovery, strain, and fitness while providing personalized recommendations.

Abbott’s involvement as a strategic investor is particularly significant. The healthcare giant brings deep expertise in diagnostics and medical devices, plus a track record in health tech innovation. This partnership could help WHOOP expand beyond fitness tracking into serious medical applications.

The context

WHOOP has been building toward this moment for over a decade since its 2012 founding. The company has now raised more than $900 million in total venture funding and claims millions of users worldwide.

The wearable market is increasingly crowded, with Apple dominating through its Watch and companies like Oura competing in the ring form factor. But WHOOP has carved out a niche among serious athletes and health-conscious professionals who want detailed biometric tracking.

Key differentiators include:

• A 14-day battery life that eliminates daily charging
• FDA-cleared ECG monitoring
• Advanced lab analysis for blood biomarkers
• Focus on actionable health insights rather than just data collection

“WHOOP has become one of the most important tools I use to support my long-term health,” said Cristiano Ronaldo, who serves as both an investor and global ambassador. “No other company has created a health platform this powerful that people are proud to wear.”

The post WHOOP raises $575 million at $10.1 billion valuation appeared first on mHealth Spot.